Welcome to our dedicated page for Calliditas Therapeutics Ab news (Ticker: CALT), a resource for investors and traders seeking the latest updates and insights on Calliditas Therapeutics Ab stock.
Calliditas Therapeutics AB (CALT) is a clinical-stage biopharmaceutical leader developing innovative therapies for rare renal and hepatic diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships shaping the future of orphan disease treatment.
Access timely announcements covering critical developments in IgA nephropathy research, NOX enzyme inhibitor advancements, and global commercialization efforts. Our curated collection includes press releases on Phase 3 trial results, FDA/EMA regulatory reviews, and licensing agreements with international partners.
Key focus areas include updates on lead product Nefecon® in IgAN therapy, setanaxib trials for fibrotic diseases, and market expansion strategies. Bookmark this page to stay informed about Calliditas' progress in addressing unmet medical needs through targeted molecular therapies.
On April 26, 2023, Calliditas Therapeutics announced the availability of its 2022 Annual Report on the company's website. The report provides insights into the company's performance, including developments in their lead product, Nefecon, which received FDA accelerated approval as TARPEYO® and conditional marketing authorization in the EU as Kinpeygo®. Additionally, Calliditas is advancing clinical trials for its NOX inhibitor product candidate, setanaxib, targeting primary biliary cholangitis and head & neck cancer. Contact for investor relations is Åsa Hillsten, available via phone or email. The company cautioned that the report contains forward-looking statements that are subject to risks and uncertainties regarding future performance.
FAQ
What is the current stock price of Calliditas Therapeutics Ab (CALT)?
What is the market cap of Calliditas Therapeutics Ab (CALT)?
